EPA 2006 Annual Scientific Meeting

New York Marriott East Side

New York City, NY

September 29-30, 2006

LEVEL 1

Alpharma

(Alpharma also supporting Houde Dinner/Lecture)

Endo Pharmaceuticals

(Endo also supporting the Bonica Luncheon/Lecture)

LEVEL 2

Celgene Corporation

Ortho-McNeil Janssen

Pfizer Inc.

LEVEL 3

Dominion Diagnostics

(Dominion Diagnostics also supporting the NEW EPA Membership Directory)

_______________________________________________________

Elan Corporation

GlaxoSmithKline / Adolor Corporation

Ligand Pharmaceuticals

Purdue Pharma LP

Wyeth Consumer Healthcare

(Wyeth also supporting the Bonica Luncheon/Lecture)

LEVEL 4

Cephalon

Elsevier

Alpharma

Alpharma develops, markets, and sells proprietary pharmaceutical products and services designed to improve the quality of life of patients and caregivers. Alpharma's first product offering is KADIAN (morphine sulfate extended-release)Capsules CII, which is proven to provide 24-hour control of chronic pain with the convenience of Once-a-Day or Twice-a-Day dosing.

Celgene Corporation

Celgene is a multinational integrated biopharmaceutical company,

incorporated in 1986 as a Delaware corporation. We are primarily engaged

in the discovery, development and commercialization of innovative

therapies designed to treat cancer and immunological diseases through

regulation of genomic and proteomic targets. Driving commercial success

and profitability are marketed products, which include REVLIMID(r)

(lenalidomide), THALOMID® (thalidomide), ALKERAN® (melphalan),

FOCALIN® (dexmethylphenidate HCl), cellular and tissue therapeutics,

as well as the RITALIN® family of drugs.

On August 31, 2000, we acquired Signal Pharmaceuticals, Inc., a

privately held San Diego-based biopharmaceuticals company focused on the

discovery and development of drugs that regulate genes associated with

diseases, which is presently a wholly owned subsidiary. On December 31,

2002, we acquired Anthrogenesis Corporation, a privately held New Jersey

based biotherapeutics company and cord blood banking business, which has

also pioneered the recovery of stem cells from human placental tissue

following the completion of a full-term, successful pregnancy.

Anthrogenesis now operates as Celgene Cellular Therapeutics ("CCT"), a

wholly owned subsidiary.

The Company, together with these diverse subsidiaries, has built a

commercialization, development, and discovery platform for drug and

cell-based therapies that allows us to both create and retain

significant value within our therapeutic franchise areas of cancer and

inflammatory diseases. This target-to-therapeutic platform integrates

both small molecule and cell-based therapies and spans the key functions

required to generate a broad, deep and diverse pipeline of new drugs and

cell therapy candidates, including:

i. cell biology, genomics, proteomics and informatics technologies for identifying and validating clinically important therapeutic targets;

ii. high throughput screening systems combined with diverse and focused compound libraries for discovering new drug leads;

iii. computational and medicinal chemistry for optimizing drug candidates;

iv. in vitro and in vivo models of disease for preclinical evaluation of drug efficacy and safety; and

v. a clinical and regulatory organization highly experienced in the successful development of pharmaceutical agents.

The ongoing development of immunomodulatory agents, cell-signaling

inhibitors, as well as cellular and tissue therapeutics may allow us to

provide physicians/clinicians with a more comprehensive and integrated

set of therapeutic solutions for managing complex human diseases such as

cancer and inflammatory-related diseases.  www.celgene.com

Cephalon

Cephalon, Inc.

41 Moores Road

Frazer, PA  19355

www.cephalon.com

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. 

GlaxoSmithKline and Adolor Corporation
Working together to advance the understanding of opioid-induced bowel dysfunction (OBD). GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer. Adolor is dedicated to the discovery, development, and commercialization of novel prescription pain products.

 

Ligand Pharmaceuticals, Inc.

Ligand Pharmaceuticals Incorporated is a high-growth, research intensive biopharmaceutical company based in San Diego. Focused on the unmet needs of patients with cancer and pain, the company has developed and markets five products in the US.

AVINZA® (morphine sulfate extended-release capsules) is a highly effective sustained-release opioid offering benefits to patients with moderate to severe chronic pain and to busy prescribers with its convenient once-daily dosing. Ask your Ligand Pain Specialist about the Chronic Pain Network™ (www.chronicpainnetwork.com) and the “Back to Active” programs.

Purdue Pharma L.P.

As a privately held pharmaceutical company founded by physicians, Purdue is focused on the needs of patients. We are dedicated to finding, developing, and bringing to market new

medicines and related products that promote health and healing.

Our professional sales representatives welcome the opportunity to discuss the latest information on our products, including Advil®  Liqui-Gels®, Alavert™, Caltrate®, Dimetapp® and Robitussin®. Wyeth Consumer Healthcare is a leader in the research and development, manufacturing and marketing of a broad range of consumer health care products.